

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

WEST**Freeform Search**

Database: US Patents Full-Text Database ▲
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins ▼

Term: iodide ion same (radionuclide or contrast agent) ▲
▼

Display: 10 **Documents in Display Format:** - **Starting with Number** 1

Generate: ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

[Search](#) [Clear](#) [Help](#) [Logout](#) [Interrupt](#)

[Main Menu](#) [Show 8 Numbers](#) [Edit 8 Numbers](#) [Preferences](#) [Cases](#)

Search History

DATE: Friday, September 27, 2002 [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ

<u>L12</u>	iodide ion same (radionuclide or contrast agent)	6	<u>L12</u>
<u>L11</u>	((424/1.11)!.CCLS.) and iodide ion	4	<u>L11</u>
<u>L10</u>	L9 and ((424/1.11)!.CCLS.)	13	<u>L10</u>
<u>L9</u>	L8 and (radionuclide or contrast agent)	269	<u>L9</u>
<u>L8</u>	I3 same (stable or stabilize or stabilizer or stabilizing)	7350	<u>L8</u>
<u>L7</u>	L6 and (radionuclide or contrast agent)	1	<u>L7</u>
<u>L6</u>	L5 same (stable or stabilize or stabilizer or stabilizing)	189	<u>L6</u>
<u>L5</u>	iodide ion	3402	<u>L5</u>
<u>L4</u>	I2 and I3	2	<u>L4</u>
<u>L3</u>	iodide or iodine or ki	185437	<u>L3</u>
<u>L2</u>	depreotide	3	<u>L2</u>
<u>L1</u>	tc-99m or tc	46135	<u>L1</u>

END OF SEARCH HISTORY

Welcome to STN International! Enter x:x

LOGINID:ssspta1619lxw

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and
IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and
ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:51:03 ON 27 SEP 2002

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 08:51:09 ON 27 SEP 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2002 HIGHEST RN 455250-99-4

DICTIONARY FILE UPDATES: 25 SEP 2002 HIGHEST RN 455250-99-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e depreotide/cn

E1	1	DEPRENYL/CN
E2	1	DEPRENYL HYDROCHLORIDE/CN
E3	1 -->	DEPREOTIDE/CN
E4	1	DEPRESOSTEROL/CN
E5	1	DEPRESSAN/CN
E6	2	DEPRESSIN/CN
E7	1	DEPRESSIN (IRIDOID)/CN
E8	1	DEPRESSIN (PHARMACEUTICAL)/CN
E9	1	DEPRESSIONOL A/CN
E10	1	DEPRESSIONOL B/CN
E11	1	DEPRESSOSIDE/CN
E12	1	DEPRESSOSIDE A/CN

=> s e3

L1 1 DEPREOTIDE/CN

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN 161982-62-3 REGISTRY

CN Cyclo(L-homocysteinyl-N-methyl-L-phenylalanyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl), (1.fwdarw.1')-thioether with 3-[(mercaptoacetyl)amino]-L-alanyl-L-lysyl-L-cysteinyl-L-lysineamide (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Cyclo(L-homocysteinyl-N-methyl-L-phenylalanyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl), (1.fwdarw.1')-sulfide with 3-[(mercaptoacetyl)amino]-L-alanyl-L-lysyl-L-cysteinyl-L-lysineamide

OTHER NAMES:

CN 84: PN: WO02060491 PAGE: 50 claimed sequence

CN **Depreotide**

CN P 829

FS PROTEIN SEQUENCE; STEREOSEARCH

DR 174510-48-6

MF C65 H96 N16 O12 S2


SR CA



LC STN Files: ADISINSIGHT, CA, CAPLUS, DIOGENES, DRUGNL, DRUGPAT, DRUGUPDATES, PROMT, TOXCENTER, USAN, USPATFULL

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

Absolute stereochemistry.

PAGE 1-A





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13 REFERENCES IN FILE CA (1962 TO DATE)
 9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 13 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.96

6.17

STN INTERNATIONAL LOGOFF AT 08:51:39 ON 27 SEP 2002

Welcome to STN International! Enter x:x

LOGINID:sssptal619lxw

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and
IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and
ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:18:07 ON 27 SEP 2002

=> fil reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:18:15 ON 27 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2002 HIGHEST RN 455250-99-4
DICTIONARY FILE UPDATES: 25 SEP 2002 HIGHEST RN 455250-99-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s depreotide/cn
L1 1 DEPREOTIDE/CN

=> fil caplus uspatfull biosis embase medline		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	4.38	4.59

FILE 'CAPLUS' ENTERED AT 09:18:38 ON 27 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 09:18:38 ON 27 SEP 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 09:18:38 ON 27 SEP 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 09:18:38 ON 27 SEP 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 09:18:38 ON 27 SEP 2002

=> s l1

L2 19 L1

=> dup rem l2

PROCESSING COMPLETED FOR L2

L3 18 DUP REM L2 (1 DUPLICATE REMOVED)

=> s l3 and iodide ion

L4 0 L3 AND IODIDE ION

=> d l3 ibib abs

L3 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:594711 CAPLUS

DOCUMENT NUMBER: 137:159312

TITLE: Stabilization of radiopharmaceutical compositions
using hydrophilic thioethers and hydrophilic

6-hydroxy

chromans

INVENTOR(S): Cyr, John E.; Pearson, Daniel A.

PATENT ASSIGNEE(S): Diatide, Inc., USA

SOURCE: PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060491	A2	20020808	WO 2001-US50423	20011024
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2000-694992	A1 20001024
			US 2000-695360	A1 20001024
			US 2000-695494	A1 20001024

AB Radiopharmaceutical compns. which are stabilized by addn. of a hydrophilic

thioether, a hydrophilic 6-hydroxy-chroman deriv., or a mixt. of a hydrophilic thioether and a hydrophilic 6-hydroxy-chroman deriv. are described. Several examples are provided demonstrating the stabilizing effects of L-methionine, Trolox, or a combination of the two on lyophilized kit prepns. contg. ^{99m}Tc-labeled depreotide, benzodiazepinedione deriv., a glycoprotein IIb/IIa receptor-binding peptide, a peptide chelator, a bisamine bisthiol chelator, or other peptides.

=> d l3 2 ibib abs

L3 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:489224 CAPLUS

DOCUMENT NUMBER: 135:97445

TITLE: Method for relieving pain associated with an internal disease site
 INVENTOR(S): Luiken, George A.
 PATENT ASSIGNEE(S): Fluoro Probe, Inc., USA
 SOURCE: PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047512	A2	20010705	WO 2000-US42661	20001206
WO 2001047512	A3	20020502		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-457498 A1 19991208

AB Methods are provided for in vivo administration of a pain-relieving drug, such as a local anesthetic (e.g. lidocaine), to an interior disease site for pain relief at the interior disease site. In the invention pain treatment methods, a subject is administered a targeting construct comprising a biol. compatible pain-relieving agent and a tumor-avid ligand or monoclonal antibody that preponderantly binds to or is taken up by the tissue assocd. with an interior disease site. Administration is by a method other than topical injection or application, such as parenteral injection. Because the pain-relieving agent is delivered by the ligand to the disease site, intractable pain situated in the interior of the body, such as is caused by various tumors, can be managed using a lower level of the pain-relieving agent then is required when the pain-relieving agent is injected in the free state.

=> d l3 3 ibib abs

L3 ANSWER 3 OF 18 USPATFULL

ACCESSION NUMBER: 2001:237454 USPATFULL
 TITLE: Method for viewing tumor tissue located within a body cavity
 INVENTOR(S): Luiken, M.D., George A., Coronado, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001055566	A1	20011227
APPLICATION INFO.:	US 2001-832297	A1	20010409 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-362805, filed on 28 Jul 1999, GRANTED, Pat. No. US 6284223		
	Continuation-in-part of Ser. No. US 1998-173190, filed on 15 Oct 1998, PENDING		

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GARY CARY WARE & FRIENDENRICH LLP, 4365 EXECUTIVE
DRIVE, SUITE 1600, SAN DIEGO, CA, 92121-2189
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
LINE COUNT: 1252

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods are provided for in vivo detection of diseased tissue in a subject, such as tumor tissue located in a body opening, by administering to the subject a biologically compatible fluorescing targeting construct that binds to or is specifically taken up by the diseased tissue. The observer directly views fluorescence emanating from the fluorescing targeting construct bound to or taken up by the diseased tissue upon irradiation of the targeting construct with excitation light having at least one wavelength in the range from 401 nm to about 495 nm, but preferably lacking light having a wavelength above about 500 nm, so as to determine the location and/or surface area of the diseased tissue in the subject. Since excitation wavelength does not penetrate through tissue, as is the practice in near IR diagnostics, the diseased or abnormal tissue is exposed to the excitation light either surgically or by means of an endoscopic device. Preferably a filter is used to filter out any wavelengths in the excitation light greater than about 500 nm.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 13 4 ibib abs

L3 ANSWER 4 OF 18 USPATFULL

ACCESSION NUMBER: 2001:173125 USPATFULL
TITLE: Method for viewing diseased tissue located within a body cavity
INVENTOR(S): Luiken, George, Coronado, CA, United States
PATENT ASSIGNEE(S): Fluoro Probe, Inc., Coronado, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6299860	B1	20011009
APPLICATION INFO.:	US 1998-173190		19981015 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Dees, Jose' G.		
ASSISTANT EXAMINER:	Jones, Dameron L.		
LEGAL REPRESENTATIVE:	Gray Cary Ware & Freidenrich, Learn, June M.		
NUMBER OF CLAIMS:	43		
EXEMPLARY CLAIM:	1		
LINE COUNT:	905		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods are provided for in vivo detection of tissue associated with a disease state in a subject, such as tissue located in a body opening.
In the invention method, the subject is administered a biologically compatible fluorescing targeting construct, the construct is allowed to bind to any target tissue present in the subject, a body part of the

subject suspected of containing the target tissue is irradiated with UV light while extraneous light to the body part is substantially eliminated, and fluorescence emanating from the fluorescing targeting construct bound to the target tissue is detected and visualized by the observer with or without the aid of an endoscope, so as to determine

the

location and size of the target tissue. The invention methods offer the advantage that diseased or abnormal tissue can be detected at interior body sites with or without the aid of an endoscopic device. Once the diseased or abnormal tissue has been identified, for example in a surgical opening, such tissue can be readily biopsied or excised surgically.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 13 5 ibib abs kwic

L3 ANSWER 5 OF 18 USPATFULL

ACCESSION NUMBER: 2001:147442 USPATFULL

TITLE: Method for viewing tumor tissue located within a body cavity

INVENTOR(S): Luiken, George, Coronado, CA, United States

PATENT ASSIGNEE(S): FluoroProbe, Inc., Coronado, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6284223	B1	20010904
APPLICATION INFO.:	US 1999-362805		19990728 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-173190, filed on 15 Oct 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Jones, Dameron L.		
LEGAL REPRESENTATIVE:	Gray Cary Ware & Freidenrich LLP, Learn, June M.		
NUMBER OF CLAIMS:	46		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1154		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods are provided for in vivo detection of tumor tissue associated with a disease state in a subject, such as tumor tissue located in body opening. In the invention method, the subject is administered a biologically compatible fluorescing targeting construct, the construct is allowed to bind to and/or be taken up by tumor tissue present in the subject, a body part of the subject suspected of containing the tumor tissue is irradiated with UV light while extraneous light to the body part is substantially eliminated, and fluorescence emanating from the fluorescing targeting construct bound to and/or taken up by the tumor tissue is directly viewed by the observer with or without the aid of an endoscope, so as to determine the location and size of the tumor tissue.

The invention methods offer the advantage that diseased or abnormal tissue can be directly viewed at interior body sites with or without

the

aid of an endoscopic device, and without the use of additional imaging equipment, for example, through a surgical opening to facilitate a procedure of biopsy or surgical excision.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 60-54-8, Tetracycline 63-68-3, Methionine, biological studies
 69-78-3
 81-88-9 154-17-6, 2-Deoxyglucose 2321-07-5 2543-43-3 2543-43-3D,
 oligomeric 22264-50-2, 1-Aminocyclobutane-1-carboxylic acid
 51110-01-1, Somatostatin 68181-17-9 72252-96-1 83150-76-9,
 Octreotide 106145-13-5 108736-35-2, Lanreotide 115616-51-8
 130838-28-7 150243-58-6 150243-59-7 150244-18-1 153177-60-7
 160854-54-6 161982-62-3, P829 199804-25-6 256504-33-3
 256504-34-4 256504-35-5 264596-75-0, P 587
 (fluorescence imaging of tumor tissue)

=> d 13 6 ibib abs

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2000:260081 CAPLUS
 DOCUMENT NUMBER: 132:290564
 TITLE: Method for viewing tumor tissue located within a body
 cavity
 INVENTOR(S): Luiken, George A.
 PATENT ASSIGNEE(S): Fluoro Probe, Inc., USA
 SOURCE: PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021576	A2	20000420	WO 1999-US21607	19991012
WO 2000021576	A3	20000713		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6299860	B1	20011009	US 1998-173190	19981015
EP 1121158	A2	20010808	EP 1999-956489	19991012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			US 1998-173190	A2 19981015
			US 1999-362805	A2 19990728
			WO 1999-US21607	W 19991012

AB Methods are provided for in vivo detection of tissue assocd. with a disease state in a subject, such as tumor tissue located in a body opening. In the invention method, the subject is administered a biol. compatible fluorescing targeting construct, the construct is allowed to bind to and/or be taken up by diseased tissue present in the subject, a body part of the subject suspected of contg. the tumor tissue is irradiated in vivo with UV light while extraneous light to the body part is substantially eliminated, and fluorescence emanating from the fluorescing targeting construct bound to and/or taken up by the tumor tissue is directly viewed by the observer with or without the aid of an endoscope, so as to det. the location and size of the tumor tissue. The invention methods offer the advantage that diseased or abnormal tissue can

be directly viewed at interior body sites with or without the aid of an endoscopic device, and without the use of addnl. imaging equipment, for example, through a surgical opening to facilitate a procedure of biopsy or surgical excision.

=> d 13 7 ibib abs

L3 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:390302 CAPLUS

DOCUMENT NUMBER: 133:39965

TITLE: A multicenter trial with a somatostatin analog 99mTc depreotide in the evaluation of solitary pulmonary nodules

AUTHOR(S): Blum, Jay; Handmaker, Hirsch; Lister-James, John; Rinne, Neal

CORPORATE SOURCE: NeoTect Solitary Pulmonary Nodule Study Group, CIGNA Healthcare of Arizona, Phoenix, AZ, USA

SOURCE: Chest (2000), 117(5), 1232-1238

CODEN: CHETBF; ISSN: 0012-3692

PUBLISHER: American College of Chest Physicians

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Objective: The affinity of various malignant neoplasms including small cell and non-small cell lung cancer for peptide analogs of somatostatin has been well documented. Depreotide is such an analog and can be complexed with technetium-99m (99mTc depreotide) for optimal imaging properties. Using this radiopharmaceutical, solitary pulmonary nodules (SPN) were previously evaluated in a successful phase II/III trial. The results of the larger multicenter phase III study using 99mTc depreotide to differentiate malignant and benign etiologies in SPN are now presented.

Methods: Patients with SPN .ltoreq. 6 cm on chest radiograph were referred

for evaluation. One hundred fourteen individuals who had an absence of a benign pattern of calcification on CT scan, age > 30 yr, and no demonstrable radiog. stability for the prior 2 yr were studied. All underwent single-photon emission CT (SPECT) with 99mTc depreotide and subsequent tissue histol. examn. Three nuclear medicine specialists blinded to histol. findings examd. the SPECT images and scored them as pos. or neg. based on the presence or absence of activity in the radiog. region of the SPN. The final result was detd. by the majority score, which was then compared with the histol. result. Results: Of the 114 individuals studied, 88 had a histol. result compatible with malignant neoplasm. 99mTc depreotide scintigraphy correctly identified 85 of this group, with three false-neg. detns. compared with histol. There were seven false-pos. detns., including six granulomas and one hamartoma. 99mTc depreotide scintigraphy correctly excluded malignancy in 19 of 26 patients with benign histol. findings. The sensitivity of this method

was 96.6% with a specificity of 73.1%. Conclusion: 99mTc depreotide scintigraphy is a safe and useful method for the noninvasive evaluation of

SPN with a sensitivity and accuracy comparable to that reported for fluorine-18 fluorodeoxyglucose positron emission tomog.

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

=> d 13 8 ibib abs

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:370600 CAPLUS

DOCUMENT NUMBER: 133:249048

TITLE: Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide radiolabeled with ^{99m}Tc or ¹⁸⁸Re

AUTHOR(S): Zinn, Kurt R.; Buchsbaum, Donald J.; Chaudhuri, Tandra

R.; Mountz, James M.; Grizzle, William E.; Rogers, Buck E.

CORPORATE SOURCE: Departments of Radiology, Radiation Oncology, and Pathology, University of Alabama at Birmingham, Birmingham, AL, USA

SOURCE: Journal of Nuclear Medicine (2000), 41(5), 887-895
CODEN: JNMEAQ; ISSN: 0161-5505

PUBLISHER: Society of Nuclear Medicine, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Gene therapy protocols require better modalities to monitor the location and level of transferred gene expression. One potential in vivo mechanism

to assess gene expression would be to image the binding of a radiolabeled peptide to a reporter receptor that is expressed in targeted tissues. This concept was tested in a tumor model using a replication-incompetent adenoviral vector encoding the human type 2 somatostatin receptor (Ad5-CMVhSSTR2). Expression of the hSSTR2 reporter was imaged using a radiolabeled, somatostatin-avid peptide (P829). Methods: Bilateral s.c. A427 tumor xenografts were established on the flanks of athymic nude

mice.

These human-origin, non-small cell lung tumors are normally neg. for hSSTR2 expression. One tumor was injected directly with Ad5-CMVhSSTR2, whereas the second tumor was injected directly with a control Ad5 vector. The mice were injected i.v. 48 h later with P829 peptide that was radiolabeled to high specific activity with ^{99m}Tc (half-life, 6 h) or ¹⁸⁸Re (half-life, 17 h). Tumors were frozen and evaluated for somatostatin receptor expression using fluorescein-labeled somatostatin. Results: The accumulation of radiolabeled P829 in hSSTR2-expressing

tumors

was easily visualized by .gamma. camera imaging 3 h after injection.

Imaging region of interest analyses and biodistribution studies confirmed a 5- to 10-fold greater accumulation of both radiolabeled P829 peptides

in

the Ad5-CMVhSSTR2-injected tumors vs. control tumors injected with

control

Ad5 vectors. Ad5-CMVhSSTR2-injected tumors accumulated 2.5-3.8

percentage

injected dose per g 3 h after injection. Only Ad5-CMVhSSTR2-injected tumors expressed somatostatin receptors, as detd. by immunohistochem.

Conclusion: These studies show the feasibility of imaging a ^{99m}Tc-labeled peptide's binding to a reporter receptor after in vivo gene transfer to tumor cells. The ¹⁸⁸Re-labeled peptide worked equally well for this imaging approach and offers the addnl. advantage of energetic .beta. decay

decay

with potential therapeutic efficacy. ^{99m}Tc and ¹⁸⁸Re are generator produced, an advantage for widespread availability and low cost, and both radioisotopes can be imaged with existing, high-resoln. modalities.

There

is great potential for using 99mTc-labeled peptides for imaging gene transfer with the hSSTR2 reporter receptor, esp. when the reporter correlates with the expression of therapeutic genes that can be included simultaneously in the gene therapy vector.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

=> d 13 9 ibib abs

L3 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
ACCESSION NUMBER: 1999:704836 CAPLUS
DOCUMENT NUMBER: 131:327610
TITLE: Labeled somatostatin analogs for imaging
cardiovascular disease
INVENTOR(S): Dean, Richard T.; Lister-James, John
PATENT ASSIGNEE(S): Diatide, Inc., USA
SOURCE: U.S., 6 pp., Cont.-in-part of U.S. Ser. No. 253,973.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5976496	A	19991102	US 1997-976995	19971124
CA 2191951	AA	19951214	CA 1995-2191951	19950601
CN 1158090	A	19970827	CN 1995-194356	19950601
ZA 9504548	A	19960315	ZA 1995-4548	19950602

PRIORITY APPLN. INFO.: US 1994-253973 A2 19940603

AB The invention provides methods and kits for detecting cardiovascular disease in a living mammal, using a labeled form of a somatostatin analog.

Suitable labels are 123I, 67Ga, 111In and 99mTc. The methods and kits of the invention provide early detection of atherosclerotic plaque, in particular, unstable atherosclerotic plaque, thus allowing therapeutic intervention prior to acute and potentially fatal incidents of cardiovascular disease. Thus, localization and in-vivo imaging of atherosclerotic plaques was carried out in hypercholesteremic rabbits using Tc-99m-labeled somatostatin analogs.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

=> d 13 10 ibib abs

L3 ANSWER 10 OF 18 USPATFULL
ACCESSION NUMBER: 1999:113713 USPATFULL
TITLE: Cyclic hexapeptide somatostatin analogues
INVENTOR(S): Dean, Richard T, Bedford, NH, United States
McBride, William, Summit, NJ, United States
Lister-James, John, Bedford, NH, United States
PATENT ASSIGNEE(S): Diatide, Inc., Londonderry, NH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5955426		19990921
	WO 9604308		19960215
APPLICATION INFO.:	US 1997-776160		19970630 (8)
	WO 1995-US9276		19950720
			19970630 PCT 371 date
			19970630 PCT 102(e) date
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-282980, filed on 29 Jul 1994		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Tsang, Cecilia J.		
LEGAL REPRESENTATIVE:	McDaniels, Patricia A., Noonan, Kevin E.		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
LINE COUNT:	898		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to therapeutic reagents and peptides, including radiotherapeutic reagents and peptides, and radiodiagnostic reagents and peptides. Specifically, the invention relates to cyclic peptide derivatives and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods for using such peptides for radiodiagnostic and radiotherapeutic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 13 11 ibib abs

L3 ANSWER 11 OF 18 USPATFULL
 ACCESSION NUMBER: 1999:88768 USPATFULL
 TITLE: Cyclic peptide somatostatin analogs
 INVENTOR(S): Dean, Richard T., Bedford, NH, United States
 McBride, William, Manchester, NH, United States
 Lister-James, John, Bedford, NH, United States
 PATENT ASSIGNEE(S): Diatech, Inc., Londonberry, NH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5932189		19990803
APPLICATION INFO.:	US 1994-282980		19940729 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose G.		
ASSISTANT EXAMINER:	Jones, Dameron		
LEGAL REPRESENTATIVE:	McDaniels, Patricia A., Noonan, Kevin E.		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1032		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to therapeutic reagents and peptides, including radiotherapeutic reagents and peptides, and radiodiagnostic reagents and peptides. Specifically, the invention relates to cyclic peptide derivatives and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods for using such peptides for radiodiagnostic and radiotherapeutic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 13 12 ibib abs

L3 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:110998 CAPLUS

DOCUMENT NUMBER: 130:322394

TITLE: The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules

AUTHOR(S): Blum, Jay E.; Handmaker, Hirsch; Rinne, Neal A.

CORPORATE SOURCE: CIGNA Healthcare of Arizona, Phoenix, AZ, USA

SOURCE: Chest (1999), 115(1), 224-232

CODEN: CHETBF; ISSN: 0012-3692

PUBLISHER: American College of Chest Physicians

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Many neoplasms including small cell cancers more densely express somatostatin-type receptors or more avidly bind somatostatin than granulomatous and other nonmalignant processes. While non-small cell neoplasms of the lung have not yet been shown to demonstrate this receptor

expression, previous studies have documented non-small cell lung cancer detection with somatostatin analog scintigraphy. This phenomenon can be conceivably exploited utilizing technetium Tc-99m P829 (P829), a unique low mol. wt. somatostatin-type receptor binding polypeptide radiopharmaceutical. The objective of this study was to det. the ability of P829 scintigraphy to noninvasively differentiate malignant and nonmalignant solitary pulmonary nodules (SPNs). The radiopharmaceutical technetium 99mTc-P829 was utilized for scintigraphy including single photon emission computed tomog. Thirty individuals with indeterminate SPNs of .gtoreq. 1 cm and significant risk factors for primary lung cancer

were identified and underwent P829 scintigraphy. Tissue diagnosis was then established by transthoracic needle biopsy specimens. Fourteen subjects demonstrated abnormal P829 scans in the region of the radiog. abnormality. Twelve of this group had biopsy specimens revealing neoplasia. Two subjects with necrotizing granuloma on biopsy specimen had

abnormal P829 scans in the region of the nodule. Sixteen subjects had no abnormal P829 tracer uptake in the region of the nodule. Fourteen subjects had benign diagnoses on biopsy specimens. One member of this group with a non-diagnostic biopsy specimen refused thoracotomy and remains radiog. stable at 24 mo of follow-up. One subject with a squamous

cell carcinoma demonstrated no P829 activity in the region of the nodule. The specificity of P829 scintigraphy based on transthoracic needle biopsy specimen was 88%. The sensitivity was 93%. P829 scintigraphy correctly identified or excluded malignancy in 27 of 30 subjects. P829 scintigraphy

reliably identified or excluded malignancy in radiog. indeterminate solitary pulmonary nodules. The sensitivity and specificity compared favorably with the reported results of F-18 fluorodeoxyglucose positron emission tomog. imaging.

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

=> d 13 13 ibib abs

L3 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:273442 CAPLUS

DOCUMENT NUMBER: 129:51472

TITLE: Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829

AUTHOR(S): Virgolini, Irene; Leimer, Maria; Handmaker, Hirsch; Lastoria, Secondo; Bischof, Claudia; Muto, Pietro; Pangerl, Thomas; Gludovacz, Doris;

Peck-Radosavljevic,

CORPORATE SOURCE: Markus; Lister-James, John; Hamilton, Gerhard; Kaserer, Klaus; Valent, Peter; Dean, Richard
Department of Nuclear Medicine, University of Vienna, Vienna, A-1090, Austria

SOURCE: Cancer Research (1998), 58(9), 1850-1859

CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Recent data suggest that somatostatin receptors (SSTRs) are expressed on various tumor cells. High-level expression of SSTR on the tumor cell surface provides the basis for the successful clin. use of radiolabeled ligands for the in vivo localization of tumor sites. We have characterized the in vitro binding properties of the novel SSTR ligand 99mTc-P829 using primary human tumors (carcinoids, breast cancers, intestinal adenocarcinomas, pheochromocytomas, small cell and non-small cell lung cancer, and melanomas; n = 28), various tumor cell lines, and COS7 cells transfected with the human SSTR (hSSTR) subtypes 1, 2, 3, 4, and 5. 99mTc-P829 bound to primary tumor cells and tumor cell lines with high affinity and high capacity. The disocn. consts. (Kd) ranged

between

1 and 20 nM. 99mTc-P829 also bound with high affinity to the transfected hSSTR2 (Kd, 2.5 nM), hSSTR5 (Kd, 2 nM), and hSSTR3 (Kd, 1.5 nM). Binding of 99mTc-P829 to hSSTR3 was found to be displaceable by unlabeled P829/([ReO]-P829), SST-14, and vasoactive intestinal peptide (VIP; IC50,

2

nM) and, less effectively, by Tyr3-octreotide (IC50, 20 nM). In contrast,

the binding of 99mTc-P829 to hSSTR2 and hSSTR5 could be displaced by P829/([ReO]-P829) and Tyr3-octreotide but not by VIP. 99mTc-P829 scintigraphy revealed in vivo binding to primary or metastatic tumor

sites

in seven of eight patients with breast cancer and six of six patients with

melanoma. In summary, our data show that 99mTc-P829 binds with high affinity to many different types of primary and cloned tumor cells.

Furthermore, our data identify hSSTR2, the VIP acceptor hSSTR3, and hSSTR5

as the resp. target receptors. Because these receptors are frequently expressed at high levels on primary tumor cells, 99mTc-P829 appears to be a promising novel peptide tracer for tumor imaging.

=> d 13 14 ibib abs

L3 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:367653 CAPLUS

DOCUMENT NUMBER: 125:52519
 TITLE: Cyclic hexapeptide somatostatin analogs for radiodiagnosis and radiotherapy
 INVENTOR(S): Dean, Richard T.; McBride, William; Lister-James, John
 PATENT ASSIGNEE(S): Lister-James, John, USA
 SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9604308	A1	19960215	WO 1995-US9276	19950720
W: AU, BR, CA, CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5932189	A	19990803	US 1994-282980	19940729
CA 2195395	AA	19960215	CA 1995-2195395	19950720
AU 9531984	A1	19960304	AU 1995-31984	19950720
AU 702917	B2	19990311		
EP 775160	A1	19970528	EP 1995-928109	19950720
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1161698	A	19971008	CN 1995-194920	19950720
BR 9508467	A	19971223	BR 1995-8467	19950720
JP 10506880	T2	19980707	JP 1995-506575	19950720
JP 3117218	B2	20001211	JP 1996-506575	19950720
ZA 9506254	A	19960313	ZA 1995-6254	19950727
US 5955426	A	19990921	US 1997-776160	19970630
PRIORITY APPLN. INFO.:			US 1994-282980	A2 19940729
			WO 1995-US9276	W 19950720

OTHER SOURCE(S): MARPAT 125:52519

AB The invention relates to therapeutic reagents and peptides, including radiotherapeutic reagents and peptides, and radiodiagnostic reagents and peptides. Specifically, the invention relates to cyclic peptide derivs. and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods for using such peptides for radiodiagnostic and radiotherapeutic purposes. Receptor-binding data are included. Localization and in vivo imaging of somatostatin receptor-expressing tumors in rats are described (no data).

=> d 13 15 ibib abs

L3 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:148249 CAPLUS

DOCUMENT NUMBER: 124:261669

TITLE: Somatostatin Receptor-Binding Peptides Labeled with Technetium-99m : Chemistry and Initial Biological Studies

AUTHOR(S): Pearson, Daniel A.; Lister-James, John; McBride, William J.; Wilson, David M.; Martel, Lawrence J.; Civitello, Edgar R.; Taylor, John E.; Moyer, Brian

R.;

Dean, Richard T.

CORPORATE SOURCE: Department of Chemistry, Diatech Inc., Londonderry, NH, 03053, USA

SOURCE: Journal of Medicinal Chemistry (1996), 39(7), 1361-71
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The synthesis of peptides which possess a high affinity for the somatostatin receptor and contain a chelator for the radionuclide technetium-99m is described. The target compds. were designed such that they would form stable, oxotechnetium(V) chelate complexes in which the site of metal coordination was well defined and remote from the receptor-binding region. Oxorhenium(V) chelate complexes of these peptides were prepd. as nonradioactive surrogates for the technetium complexes. Peptide oxorhenium complexes and Tc-99m complexes eluted closely upon HPLC anal. The receptor-binding affinities of both the free and rhenium-coordinated species were measured in vitro. The binding affinities of the free peptides (K_i 's in the 0.25-10 nM range) compared favorably with [DTPA]octreotide ($K_i = 1.6$ nM), which, as the indium-111 complex, is already approved for somatostatin-type receptor (SSTR)-expressing tumor imaging in the United States and Europe. Furthermore, the rhenium-coordinated peptides had binding affinities which, in many cases, were higher than those of the corresponding free peptides, with several complexes having $K_i = 0.1$ nM. Some of the more potent SSTR-binding peptides were labeled with technetium-99m and assessed

in an in vivo study with tumor-bearing rats. The 99mTc-labeled peptides prepd. in this study should be useful as SSTR-expressing tumor-imaging agents due to their high SSTR-binding affinities, ease of prepn., and, because they are low mol. wt. peptides, expected pharmacokinetics characterized by rapid tracer excretion from the body resulting in high-contrast images.

=> d 13 16 ibib abs

L3 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:426626 CAPLUS

DOCUMENT NUMBER: 125:136537

TITLE: Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides

AUTHOR(S): Vallabhajosula, Shankar; Moyer, Brian R.;
Lister-James, John; McBride, Bill J.; Lipszyc,

Helena;

CORPORATE SOURCE: Lee, Hiram; Bastidas, Diago; Dean, Richard T.
Department Radiology, Mount Sinai Medical Center, New York, NY, 10029, USA

SOURCE: Journal of Nuclear Medicine (1996), 37(6), 1016-1022
CODEN: JNMEAQ; ISSN: 0161-5505

PUBLISHER: Society of Nuclear Medicine

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We report here the results of studies on the in vitro receptor binding affinity, in vivo tumor uptake and biodistribution of two 99mTc-labeled peptides. Peptides P587 and P829 were synthesized by N-.alpha.-Fmoc peptide chem., purified by reversed-phase HPLC and characterized by fast-atom bombardment mass spectrometry. The peptides were labeled with 99mTc by ligand exchange from 99mTc-glucuheptonate. In vitro

somatostatin

receptors (SSTR)-binding affinities of P587, P829 and their oxorhenium complexes, [DTPA]octreotide and In-[DTPA]octreotide were detd. in an inhibition assay using AR42J rat pancreatic tumor cell membranes and

125I-[Tyr3]somatostatin-14 as the probe. In vivo single- and dual-tracer studies of 99mTc peptides and 111In-[DTPA]octreotide were carried out using Lewis rats bearing CA20948 rat pancreatic tumor implants. Technetium-99m-P587 and 99mTc-P829 of high-specific activity (>60 Ci (2.2 TBq)/mmole) were prepd. in >90% radiochem. yield. P587 and P829 had a Ki = 2.5 nM and 10 nM, resp. [ReO]P587 and [ReO]P829, representing the

99mTc

complexes, had Ki = 0.15 nM and 0.32 nM, resp. In comparison, [DTPA]octreotide and In-[DTPA]octreotide had Ki = 1.6 and 1.2 nM, resp. In vivo tumor uptake of 99mTc-P587 and 99mTc-P829 was high (4.1 and 4.9%ID/g at 90 min postinjection compared to 2.9% for 111In-[DTPA]octreotide). Tumor/blood and tumor/muscle ratios at 90 min postinjection were 6 and 33 for 99mTc-P587, 21 and 68 for 99mTc-P829, and 22 and 64 for 111In-[DTPA]octreotide. The high SSTR-binding affinity and high, receptor-specific and saturable in vivo tumor uptake indicate that 99mTc-P587 and 99mTc-P829 are promising radiotracers for the clin. detection of SSTR-expressing tumors and other tissues by 99mTc gamma scintigraphy.

=> d 13 17 ibib abs

L3 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:155533 CAPLUS
DOCUMENT NUMBER: 124:212160
TITLE: Monoamine, diamide, thiol-containing metal chelating agents
INVENTOR(S): Mcbride, William; Dean, Richard T.
PATENT ASSIGNEE(S): Diatech, Inc., USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9533497	A1	19951214	WO 1995-US6914	19950601
W: AU, BR, CA, CN, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2191951	AA	19951214	CA 1995-2191951	19950601
AU 9526944	A1	19960104	AU 1995-26944	19950601
AU 707040	B2	19990701		
BR 9507917	A	19970812	BR 1995-7917	19950601
CN 1158090	A	19970827	CN 1995-194356	19950601
EP 804252	A2	19971105	EP 1995-922159	19950601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE				
JP 10501531	T2	19980210	JP 1995-501181	19950601
ZA 9504548	A	19960315	ZA 1995-4548	19950602
PRIORITY APPLN. INFO.:			US 1994-253973	A 19940603
			WO 1995-US6914	W 19950601

OTHER SOURCE(S): MARPAT 124:212160

AB The invention relates to reagents useful in prepg. radiolabeled diagnostic

and therapeutic agents (radiopharmaceuticals). Specifically, the invention provides such reagents that are monoamine, diamide, and thiol-contg. metal chelators. Methods of making such reagents, and methods of using the radiopharmaceuticals produced therefrom are also

provided.

=> d 13 18 ibib abs

L3 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:465577 CAPLUS
DOCUMENT NUMBER: 122:234388
TITLE: Radiolabeled somatostatin-derived peptides for
imaging
and therapeutic uses
INVENTOR(S): Dean, Richard T.; McBride, William; Lister-James,
John
PATENT ASSIGNEE(S): Diatech, Inc., USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9500553	A1	19950105	WO 1994-US6274	19940603
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9470990	A1	19950117	AU 1994-70990	19940603
AU 701083	B2	19990121		
EP 720621	A1	19960710	EP 1994-920076	19940603
EP 720621	B1	20010207		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, SE				
AT 199089	E	20010215	AT 1994-920076	19940603
US 6051206	A	20000418	US 1996-592323	19960506
PRIORITY APPLN. INFO.:			US 1993-92335	A2 19930715
			WO 1993-US6029	A 19930623
			US 1993-92355	A 19930715
			WO 1994-US6274	W 19940603

OTHER SOURCE(S): MARPAT 122:234388

AB Therapeutic reagents and peptides, including radiotherapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labeled radiodiagnostic agents, are disclosed. Specifically, the invention relates to cyclic peptide derivs. and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods and kits for making, radiolabeling, and using such peptides for radiodiagnostic and radiotherapeutic purposes. The invention specifically relates to cyclic peptide derivs. and analogs of somatostatin radiolabeled with technetium-99m and uses thereof as scintigraphic imaging agents. The invention also specifically relates to cyclic peptide derivs. and analogs of somatostatin radiolabeled with cytotoxic radioisotopes (e.g. 186Re, 188Re) for use as radiotherapeutic agents. Methods and kits for making, radiolabeling, and using such peptides diagnostically and therapeutically in a mammalian body are also provided. Data for binding of the analogs to

somatostatin receptors is included, as is use in imaging of somatostatin receptor-expressing tumors.

=> e manchanda rajesh/au

E1	1	MANCHANDA RACHNA/AU
E2	14	MANCHANDA RAHUL/AU
E3	13 -->	MANCHANDA RAJESH/AU
E4	2	MANCHANDA RAMA/AU
E5	1	MANCHANDA RAMAN/AU
E6	5	MANCHANDA RANJIT/AU
E7	1	MANCHANDA RAVINDER KUMAR/AU
E8	13	MANCHANDA ROHIT/AU
E9	1	MANCHANDA ROOPAK/AU
E10	30	MANCHANDA S/AU
E11	295	MANCHANDA S C/AU
E12	1	MANCHANDA S C M/AU

=> s e3

L5 13 "MANCHANDA RAJESH"/AU

=> dup rem l5

PROCESSING COMPLETED FOR L5

L6 13 DUP REM L5 (0 DUPLICATES REMOVED)

=> s l6 and iodid

L7 0 L6 AND IODID

=> s l6 and iodide

L8 0 L6 AND IODIDE

=> s l6 and depreotide

L9 0 L6 AND DEPREOTIDE

=> s l6 and radionuclide

L10 0 L6 AND RADIONUCLIDE

=> s l6 and contrast agent

L11 0 L6 AND CONTRAST AGENT

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	59.94	64.53
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-8.05	-8.05

STN INTERNATIONAL LOGOFF AT 09:24:33 ON 27 SEP 2002